Literature DB >> 18824038

Treating lysosomal storage disorders: current practice and future prospects.

Frances M Platt1, Robin H Lachmann.   

Abstract

There are over 40 human disease states that are caused by defects in various aspects of lysosomal function. Over the past two decades there has been dramatic progress in the development and evaluation of therapies for lysosomal storage disorders, several of which are now in routine clinical use or in clinical trials. The greatest current challenge is in developing effective therapies for treating the CNS manifestations of these complex disorders. In this article, we will review the current therapies/approaches being considered for treating lysosomal storage diseases and give a perspective on the scientific, medical, social and ethical issues they raise.

Entities:  

Mesh:

Year:  2008        PMID: 18824038     DOI: 10.1016/j.bbamcr.2008.08.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  28 in total

Review 1.  Pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Cinzia Maria Bellettato; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-04-29       Impact factor: 4.982

2.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

Review 3.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

4.  Gateway to the diseased brain.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

5.  Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Kim M Hemsley; John J Hopwood
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

Review 6.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

7.  Epidemiological, clinical and biochemical characterization of the p.(Ala359Asp) SMPD1 variant causing Niemann-Pick disease type B.

Authors:  Mariana Acuña; Pablo Martínez; Carol Moraga; Xingxuan He; Mauricio Moraga; Bessie Hunter; Peter Nuernberg; Rodrigo A Gutiérrez; Mauricio González; Edward H Schuchman; José Luis Santos; Juan Francisco Miquel; Paulina Mabe; Silvana Zanlungo
Journal:  Eur J Hum Genet       Date:  2015-04-29       Impact factor: 4.246

8.  Reference values for lysosomal enzymes activities using dried blood spots samples - a Brazilian experience.

Authors:  Karen B Müller; Mayra Db Rodrigues; Vanessa G Pereira; Ana M Martins; Vânia D'Almeida
Journal:  Diagn Pathol       Date:  2010-09-29       Impact factor: 2.644

9.  Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Authors:  John Marshall; Karen M Ashe; Dinesh Bangari; KerryAnne McEachern; Wei-Lien Chuang; Joshua Pacheco; Diane P Copeland; Robert J Desnick; James A Shayman; Ronald K Scheule; Seng H Cheng
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

Review 10.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.